

Hilde Furberg AGM Proposed Board Member Bio

Hilde Furberg is currently an independent advisor and professional Board member. She has global leadership experience both as a Board member and through her 35+ years in global sales, marketing, strategy and management in the international Pharma/Biotech industries. She has management expertise in public and private companies of varying sizes. Her most recent role was European Head of Rare Disease Europe/General Manager and Senior Vice President Rare Diseases EMEA at Genzyme/Sanofi Genzyme. Hilde was also the General Manager at Pharmalink and Baxter Healthcare. She holds a Master of Science in Chemistry from the University of Oslo, Norway.

Current Board assignments are:

Bio-Me, since Feb-21 (Private, Oslo, Norway)

OncoZenge, since Dec-20 (Listed in Stockholm, Sweden)

PCI Biotech, since May-19 (Listed in Oslo, Norway)

Tappin, since Nov-18 (Private, Oslo, Norway)

Calliditas, since Jan-14, Chairman Dec-15 to Dec-16 (Dual Listed Stockholm and Nasdaq NY)

Professional Advisor: Investinor, Pharma/Biotech since Nov-18

Previous Board assignments include:

CombiGene, Board Member May-19 – June 2020 (Listed in Stockholm, Sweden)

Blueprint Genetics, Chairman of Board Nov-18 – Jan-20 (Private owned Helsinki, Finland sold to Quest Diagnostics)

BerGenBio ASA, Board Member June-15- March 2019, Chairman Feb-16 to Jan-17 (Listed in Oslo, Norway April 2017)

Algeta ASA, Board Member April 2013- March 2014 (Listed in Oslo, Norway, Sold to Bayer 2.9B\$ in March-14)

Clavis, Board Member May 2012-April 2013 (Listed in Oslo, Norway)

Pronova, Board Member May 2011- Feb 2013 (Listed in Oslo, Norway, Sold to BASF 845M\$, Feb-13)